Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
70.98
-1.06 (-1.47%)
At close: Feb 20, 2026, 4:00 PM EST
70.48
-0.50 (-0.70%)
Pre-market: Feb 23, 2026, 6:57 AM EST
Halozyme Therapeutics Revenue
In the year 2025, Halozyme Therapeutics had annual revenue of $1.40B with 37.55% growth. Halozyme Therapeutics had revenue of $451.77M in the quarter ending December 31, 2025, with 51.60% growth.
Revenue (ttm)
$1.40B
Revenue Growth
+37.55%
P/S Ratio
6.00
Revenue / Employee
$3,301,681
Employees
423
Market Cap
8.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 381.29M | 37.55% |
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
| Dec 31, 2018 | 151.86M | -164.75M | -52.04% |
| Dec 31, 2017 | 316.61M | 169.92M | 115.84% |
| Dec 31, 2016 | 146.69M | 11.63M | 8.61% |
| Dec 31, 2015 | 135.06M | 59.72M | 79.28% |
| Dec 31, 2014 | 75.33M | 20.54M | 37.47% |
| Dec 31, 2013 | 54.80M | 12.47M | 29.47% |
| Dec 31, 2012 | 42.33M | -13.76M | -24.54% |
| Dec 31, 2011 | 56.09M | 42.46M | 311.67% |
| Dec 31, 2010 | 13.62M | -47.19K | -0.35% |
| Dec 31, 2009 | 13.67M | 4.91M | 55.99% |
| Dec 31, 2008 | 8.76M | 4.96M | 130.66% |
| Dec 31, 2007 | 3.80M | 2.82M | 287.02% |
| Dec 31, 2006 | 981.75K | 854.54K | 671.76% |
| Dec 31, 2005 | 127.21K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Axsome Therapeutics | 561.26M |
| Krystal Biotech | 389.13M |
| Cytokinetics | 87.21M |
| ImmunityBio | 82.56M |
| Kymera Therapeutics | 43.74M |
HALO News
- 4 days ago - Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge - Seeking Alpha
- 5 days ago - Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE - PRNewsWire
- 12 days ago - Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - PRNewsWire
- 20 days ago - Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth - Seeking Alpha
- 25 days ago - Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript - Seeking Alpha
- 26 days ago - Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance - PRNewsWire
- 4 weeks ago - Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - PRNewsWire